A Conversation with Tom Hudson
AbbVie’s Chief Scientific Officer
Our Science: First, Faster, and for Patients
At AbbVie, our R&D teams are chasing bold goals. The therapies and solutions that no one else has achieved or even attempted. And we want to be there first. That's what we go after every day for our patients.
Our research & development approach
Science and innovation are the lifeblood of our company. From drug discovery to clinical trials to regulatory approval, we're pursuing new ways to address patients' most challenging health issues.
Since our launch in 2013, we've invested more than $55 billion in R&D. This enables us to discover and deliver innovative medicines and products that solve serious health issues, enhance people's lives today, and address tomorrow's medical challenges.
We focus on core areas where our proven expertise and bold thinking have the greatest potential to solve unmet needs. These areas are oncology, immunology, neuroscience, eye care, medical aesthetics and other specialty areas.
An inside look at the creation of BOTOX ® (onabotulinumtoxinA)
In this episode of Discovery Files, we hear the origin story of this medication from AbbVie’s Mitchell Brin, M.D., SVP of R&D and Chief Scientific Officer for BOTOX® and neurotoxins.
Please see BOTOX® full Product Information, including Boxed Warning and Medication Guide.
Please see BOTOX® Cosmetic full Product Information, including Boxed Warning and Medication Guide.
Discovery Files:
onabotulinumtoxinA
People
To develop innovative medicines, you need innovative people. Our teams collaborate across disciplines to connect people and ideas, fueling a culture of curiosity and problem-solving.
Pipeline
Our R&D work fuels a dynamic and diverse pipeline that continues to advance and deliver medicines and solutions for patients.
Performance
The need to do more for patients motivates our R&D work. By investing in boundary-pushing approaches, we aim to advance programs with a stronger probability of success and move assets forward faster.
Progress
~50
new molecular entities
Programs
75
+
clinical programs
Priorities
Core focus areas:
impact
75
+
conditions treated
investment
$7.1
b
R&D investment in 2022
A community of global thinkers
To develop innovative medicines, you need innovative people — lots of them. We have robust teams of biologists, chemists, clinicians, mathematicians, data scientists, engineers, and others working side by side with colleagues in regulatory affairs, patient safety, manufacturing and more. Our teams collaborate across disciplines to connect people and ideas, fueling a culture of curiosity and problem-solving.
Get Involved
Interested in joining our team of innovative scientists and researchers?
Popular pages
External links
Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.
Copyright © 2023 AbbVie Inc. North Chicago, Illinois, U.S.A.
